Escalated BEACOPP Plus Rituximab in Advanced Hodgkin Lymphoma Fails to Improve Outcomes

Adding rituximab to an escalated regimen of BEACOPP did not improve progression-free survival in patients with advanced-stage Hodgkin lymphoma.

Source: CancerNetwork - March 11, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news